2026-04-13T00:12:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/110802024-06-06T08:37:37Zcom_2072_378070com_2072_378040col_2072_378092

2024-06-06T08:37:37Z urn:hdl:11351/11080 Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management Suito Alcántara, Milagros Campoy, Desirée Benítez Hidalgo, Olga Martinez Garcia, Maria Fernanda Olivera, Pável E. Gironella, Mercedes Juarez-Gimenez, Juan Carlos Trombosi Vena porta Hemofília Sang - Coagulació - Factor IX DISEASES::Cardiovascular Diseases::Vascular Diseases::Embolism and Thrombosis::Thrombosis ANATOMY::Cardiovascular System::Blood Vessels::Veins::Portal System::Portal Vein DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::Hemophilia B ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::embolia y trombosis::trombosis ANATOMÍA::sistema cardiovascular::vasos sanguíneos::venas::sistema porta::vena porta ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::hemofilia B Chronic diseases; Hematology; Pharmacology and pharmacy Malalties cròniques; Hematologia; Farmacologia i farmàcia Enfermedades crónicas; Hematología; Farmacología y farmacia Key Clinical Message The increased life expectancy in patients with hemophilia (PwH) over the last years has raised the incidence of comorbidities, including thromboembolic events. Thromboembolic events are rare in PwH and most of them occur in the presence of exogenous risk factors. There is still scarce scientific evidence on the optimal antithrombotic treatment and management approach in this population. In the hemophilic population thromboembolic events are rare. Most of them are often multifactorial and occur in the presence of both exogenous (orthopedic surgery, intensive replacement therapy, use of central venous catheters…) and endogenous (cardiovascular diseases) risk factors. We describe the case of a 43-year-old patient with severe hemophilia B (sHB) receiving prophylaxis with eftrenonacog alfa (rFIXFc) and antithrombotic treatment due to portal vein thrombosis. The patient was treated with extended half- life factor IX (EHL-FIX) prophylaxis maintaining higher trough levels to avoid new bleeding episodes associated to the underlying disease and the use of antithrombotic therapy with low molecular weight heparin. EHL-FIX concentrates allow prolonged intervals between intravenous infusions and higher hemostatic protection thanks to increased factor trough levels. This current case report provides clinical evidence in antithrombotic management in a patient with severe hemophilia B. 2024-06-06T08:37:37Z 2024-06-06T08:37:37Z 2024-02-19T13:51:56Z 2024-02-19T13:51:56Z 2024-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/11080 Clinical Case Reports;12(2) https://doi.org/10.1002/ccr3.8121 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Wiley Scientia